Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

A. M. M. Eggermont; V. Chiarion-Sileni; J. J. Grob; R. Dummer; J. D. Wolchok; H. Schmidt; O. Hamid; C. Robert; P. A. Ascierto; J. M. Richards; C. Lebbe; V. Ferraresi; M. Smylie; J. S. Weber; M. Maio; F. Hosein; V. de Pril; M. Kicinski; S. Suciu; A. Testori

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

A. M. M. Eggermont, V. Chiarion-Sileni, J. J. Grob, R. Dummer, J. D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P. A. Ascierto, J. M. Richards, C. Lebbe, V. Ferraresi, M. Smylie, J. S. Weber, M. Maio, F. Hosein, V. de Pril, M. Kicinski, S. Suciu, A. Testori

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Since 2015, adjuvant therapy with ipilimumab is an approved treatment for stage III melanoma based on a significantly prolonged recurrence-free survival (RFS). At a median follow-up of 5.3 years, RFS, distant metastasis-free survival (DMFS) and overall survival (OS) were each significantly prolonged in the ipilimumab group compared with the placebo group, despite a 53.3% (ipilimumab) versus 4.6% (placebo) treatment discontinuation rate due to adverse events. We present now long-term follow-up results of this European Organisation for Research and Treatment of Cancer 18071 trial. PATIENTS, METHODS AND RESULTS: A total of 99 sites randomised 951 patients with stage III cutaneous melanoma (excluding lymph node metastasis

Original language	Italian
Pages (from-to)	1-10
Number of pages	10
Journal	European Journal of Cancer
Volume	119
Publication status	Published - 2019

Cite this

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S., & Testori, A. (2019). Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 119, 1-10.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. / Eggermont, A. M. M.; Chiarion-Sileni, V.; Grob, J. J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; Lebbe, C.; Ferraresi, V.; Smylie, M.; Weber, J. S.; Maio, M.; Hosein, F.; de Pril, V.; Kicinski, M.; Suciu, S.; Testori, A.

In: European Journal of Cancer, Vol. 119, 2019, p. 1-10.

Research output: Contribution to journal › Article › peer-review

Eggermont, AMM, Chiarion-Sileni, V, Grob, JJ, Dummer, R, Wolchok, JD, Schmidt, H, Hamid, O, Robert, C, Ascierto, PA, Richards, JM, Lebbe, C, Ferraresi, V, Smylie, M, Weber, JS, Maio, M, Hosein, F, de Pril, V, Kicinski, M, Suciu, S & Testori, A 2019, 'Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial', European Journal of Cancer, vol. 119, pp. 1-10.

Eggermont, A. M. M. ; Chiarion-Sileni, V. ; Grob, J. J. ; Dummer, R. ; Wolchok, J. D. ; Schmidt, H. ; Hamid, O. ; Robert, C. ; Ascierto, P. A. ; Richards, J. M. ; Lebbe, C. ; Ferraresi, V. ; Smylie, M. ; Weber, J. S. ; Maio, M. ; Hosein, F. ; de Pril, V. ; Kicinski, M. ; Suciu, S. ; Testori, A. / Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. In: European Journal of Cancer. 2019 ; Vol. 119. pp. 1-10.

@article{949db3ba6fa04ce69707712658bc8a67,

title = "Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial",

abstract = "BACKGROUND: Since 2015, adjuvant therapy with ipilimumab is an approved treatment for stage III melanoma based on a significantly prolonged recurrence-free survival (RFS). At a median follow-up of 5.3 years, RFS, distant metastasis-free survival (DMFS) and overall survival (OS) were each significantly prolonged in the ipilimumab group compared with the placebo group, despite a 53.3% (ipilimumab) versus 4.6% (placebo) treatment discontinuation rate due to adverse events. We present now long-term follow-up results of this European Organisation for Research and Treatment of Cancer 18071 trial. PATIENTS, METHODS AND RESULTS: A total of 99 sites randomised 951 patients with stage III cutaneous melanoma (excluding lymph node metastasis ",

keywords = "Adjuvant therapy, Ipilimumab, Long-term results, Melanoma, Phase III trial, Stage III",

author = "Eggermont, {A. M. M.} and V. Chiarion-Sileni and Grob, {J. J.} and R. Dummer and Wolchok, {J. D.} and H. Schmidt and O. Hamid and C. Robert and Ascierto, {P. A.} and Richards, {J. M.} and C. Lebbe and V. Ferraresi and M. Smylie and Weber, {J. S.} and M. Maio and F. Hosein and {de Pril}, V. and M. Kicinski and S. Suciu and A. Testori",

note = "LR: 20190906; CI: Copyright (c) 2019; JID: 9005373; OTO: NOTNLM; 2019/07/04 00:00 [received]; 2019/07/05 00:00 [accepted]; 2019/08/11 06:00 [pubmed]; 2019/08/11 06:00 [medline]; 2019/08/11 06:00 [entrez]; aheadofprint M1 - Journal Article",

year = "2019",

language = "Italian",

volume = "119",

pages = "1--10",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

AU - Eggermont, A. M. M.

AU - Chiarion-Sileni, V.

AU - Grob, J. J.

AU - Dummer, R.

AU - Wolchok, J. D.

AU - Schmidt, H.

AU - Hamid, O.

AU - Robert, C.

AU - Ascierto, P. A.

AU - Richards, J. M.

AU - Lebbe, C.

AU - Ferraresi, V.

AU - Smylie, M.

AU - Weber, J. S.

AU - Maio, M.

AU - Hosein, F.

AU - de Pril, V.

AU - Kicinski, M.

AU - Suciu, S.

AU - Testori, A.

N1 - LR: 20190906; CI: Copyright (c) 2019; JID: 9005373; OTO: NOTNLM; 2019/07/04 00:00 [received]; 2019/07/05 00:00 [accepted]; 2019/08/11 06:00 [pubmed]; 2019/08/11 06:00 [medline]; 2019/08/11 06:00 [entrez]; aheadofprint M1 - Journal Article

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Since 2015, adjuvant therapy with ipilimumab is an approved treatment for stage III melanoma based on a significantly prolonged recurrence-free survival (RFS). At a median follow-up of 5.3 years, RFS, distant metastasis-free survival (DMFS) and overall survival (OS) were each significantly prolonged in the ipilimumab group compared with the placebo group, despite a 53.3% (ipilimumab) versus 4.6% (placebo) treatment discontinuation rate due to adverse events. We present now long-term follow-up results of this European Organisation for Research and Treatment of Cancer 18071 trial. PATIENTS, METHODS AND RESULTS: A total of 99 sites randomised 951 patients with stage III cutaneous melanoma (excluding lymph node metastasis

AB - BACKGROUND: Since 2015, adjuvant therapy with ipilimumab is an approved treatment for stage III melanoma based on a significantly prolonged recurrence-free survival (RFS). At a median follow-up of 5.3 years, RFS, distant metastasis-free survival (DMFS) and overall survival (OS) were each significantly prolonged in the ipilimumab group compared with the placebo group, despite a 53.3% (ipilimumab) versus 4.6% (placebo) treatment discontinuation rate due to adverse events. We present now long-term follow-up results of this European Organisation for Research and Treatment of Cancer 18071 trial. PATIENTS, METHODS AND RESULTS: A total of 99 sites randomised 951 patients with stage III cutaneous melanoma (excluding lymph node metastasis

KW - Adjuvant therapy

KW - Ipilimumab

KW - Long-term results

KW - Melanoma

KW - Phase III trial

KW - Stage III

M3 - Articolo

VL - 119

SP - 1

EP - 10

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -